Recent News

• 09.04.2025 - Cantor Global Healthcare Conference 2025
• 09.03.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 09.03.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 08.25.2025 - Fate Therapeutics to Present at Upcoming Investor Conferences
• 08.12.2025 - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
• 08.12.2025 - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
• 08.05.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 07.10.2025 - Next-Generation Off-the-Shelf CAR T-Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
• 07.10.2025 - Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - EX-99.1 EX-99.1
• 08.12.2025 - 8-K Current report
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2025 - 144 Report of proposed sale of securities
• 08.04.2025 - 144 Report of proposed sale of securities
• 07.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors